Loading stock…

UroGen Pharma Ltd. (URGN) Stock Verdict & Ratings | Investment Bastion

Stock Verdict·Updated 1d ago

UroGen Pharma Ltd.

URGNMarket cap $2.03BPrice $41.4

Country🇺🇸United States

SectorHealthcare

IndustryBiotechnology

UroGen develops non-surgical treatments for urothelial and specialty cancers, turning bladder chemo into a simple in-office instillation. Its flagship drug, Jelmyto, is the first FDA-approved therapy that dissolves tumors without surgery, reshaping urologic cancer care.

In Bastion Portfolios?

52W Return+144%Global Market +16%?

01Key Ratings

How does this stock score across Bastion factors?

Growth

Historical Revenue

Rev CAGR (3y)+19%9

Revenue Forecast

Rev CAGR (1y)+194%10

Rev CAGR (3y)+82%10

Rev CAGR (5y)+53%10

Earnings Forecast

EPS Growth Y+1Loss1

EPS Growth Y+20%5

EPS Growth Y+3+129%10

Quality

Margins

EBIT Margin-35%1

Net Income Margin-52%1

Free Cash Flow Margin-84%1

Debt

Net Debt/EBITDAna–

Efficiency

ROEna–

ROA-42%1

Earnings Stabilityna–

GEAR+WEAK22

Overall rating across all five factors

Value

Price Multiples

P/E Ratio (Forward)243

P/E Ratio (Forward 3y)108

P/BVna–

EV Multiples

EV/EBITDA Fwd1201

EV/EBIT Fwd891

Yield

Free Cash Flow Yield-7.9%1

Dividend Yieldna–

Momentum

Short term

1 month return-6%4

3 month return+10%8

YTD return+77%10

Mid term

Price vs 52wHigh82%5

1 year return+146%10

Long term

3 year return+202%9

5 year return+142%8

Risk Shield

Price Risk

Beta1.23

Volatility63%2

Free Cash Flow

Free Cash Flow Margin-84%1

Free Cash Flow Yield-7.9%1

Quality

ROCE-38%1

Earnings Stabilityna–

Net Debt/EBITDAna–

02Growth

Is it actually growing, and how fast?

URGNUroGen Pharma

Revenue FY25$110M

GROWTH RATING↗

VERY STRONG95 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+19%9

Revenue, next 1Y+194%10

Revenue, next 3Y, CAGR+82%10

Revenue, next 5Y, CAGR+53%10

EARNINGS FORECAST▾SCORE

EPS growth, FY26ELoss1

EPS growth, FY27E0%5

EPS growth, FY28E+129%10

GROWTH ASSESSMENT

STRENGTHS

It out-grows 95% of companies worldwide.

Revenue grew 19%/yr over the last 3 years, ahead of 80% of companies worldwide.9/10

Revenue is set to grow 82%/yr over the next 3 years, ahead of most of the market.10/10

Revenue grew 19%/yr over the last 3 years and is set to grow 82%/yr from here.

The runway holds up: revenue is set to grow 53%/yr over five years.10/10

WATCH

None flagged.

WEAKNESSES

The company is loss-making, so its revenue growth is not backed by profit yet.

BOTTOM LINE

Top-Line Rocket

A top-tier grower that's speeding up. The one thing to watch: the company is not profitable yet.

03Price Momentum

Is the market behind it right now?

MOMENTUM RATING↗

STRONG77 / 100

SHORT-TERM RETURNS▾SCORE

1-month return-6%4

3-month return+10%8

YTD return+77%10

MID & LONG-TERM▾SCORE

% of 52-week high82%5

1-year return+146%10

3-year return+202%9

5-year return+142%8

MOMENTUM ASSESSMENT

STRENGTHS

Magnificent long-term results. Long-term holders have seen +202% over three years and +142% over five, ahead of 80% of the market.

It's up 146% over the past year, but 18% below its 52-week high. That is clearly ahead of the market.

Strong recent results. The stock is outperforming over three months (+10%) and so far this year (+77%).

WATCH

Returns sit at the market level over the past month (-6%).

WEAKNESSES

None flagged.

BOTTOM LINE

Momentum Leader

Short- and long-term returns both rank among the best globally. The market is behind it — a core fit for momentum strategies.

04Value

Are you paying a fair price for it?

Stop guessing on UroGen Pharma Ltd.. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community

Loading charts…

02Growth

Is it actually growing, and how fast?

URGNUroGen Pharma

Revenue FY25$110M

GROWTH RATING↗

VERY STRONG95 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+19%9

Revenue, next 1Y+194%10

Revenue, next 3Y, CAGR+82%10

Revenue, next 5Y, CAGR+53%10

EARNINGS FORECAST▾SCORE

EPS growth, FY26ELoss1

EPS growth, FY27E0%5

EPS growth, FY28E+129%10

GROWTH ASSESSMENT

STRENGTHS

It out-grows 95% of companies worldwide.

Revenue grew 19%/yr over the last 3 years, ahead of 80% of companies worldwide.9/10

Revenue is set to grow 82%/yr over the next 3 years, ahead of most of the market.10/10

Revenue grew 19%/yr over the last 3 years and is set to grow 82%/yr from here.

The runway holds up: revenue is set to grow 53%/yr over five years.10/10

WATCH

None flagged.

WEAKNESSES

The company is loss-making, so its revenue growth is not backed by profit yet.

BOTTOM LINE

Top-Line Rocket

A top-tier grower that's speeding up. The one thing to watch: the company is not profitable yet.

03Price Momentum

Is the market behind it right now?

MOMENTUM RATING↗

STRONG77 / 100

SHORT-TERM RETURNS▾SCORE

1-month return-6%4

3-month return+10%8

YTD return+77%10

MID & LONG-TERM▾SCORE

% of 52-week high82%5

1-year return+146%10

3-year return+202%9

5-year return+142%8

MOMENTUM ASSESSMENT

STRENGTHS

Magnificent long-term results. Long-term holders have seen +202% over three years and +142% over five, ahead of 80% of the market.

It's up 146% over the past year, but 18% below its 52-week high. That is clearly ahead of the market.

Strong recent results. The stock is outperforming over three months (+10%) and so far this year (+77%).

WATCH

Returns sit at the market level over the past month (-6%).

WEAKNESSES

None flagged.

BOTTOM LINE

Momentum Leader

Short- and long-term returns both rank among the best globally. The market is behind it — a core fit for momentum strategies.

04Value

Are you paying a fair price for it?

Stop guessing on UroGen Pharma Ltd.. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community